Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.

Richard A. Ward, Mark J. Anderton, Susan Ashton, Paul A. Bethel, Matthew Box, Sam Butterworth, Nicola Colclough, Christopher G. Chorley, Claudio Chuaqui, Darren A. E. Cross, Les A. Dakin, Judit É. Debreczeni, Cath Eberlein, M. Raymond V. Finlay, George B. Hill, Matthew Grist, Teresa C. M. Klinowska, Clare Lane, Scott Martin, Jonathon P. Orme, Peter Smith, Fengjiang Wang, Michael J. Waring, Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR) Journal of Medicinal Chemistry. ,vol. 56, pp. 7025- 7048 ,(2013) , 10.1021/JM400822Z

Anatolie Dobrov, Simone Göschl, Michael A. Jakupec, Ana Popović-Bijelić, Astrid Gräslund, Peter Rapta, Vladimir B. Arion, A highly cytotoxic modified paullone ligand bearing a TEMPO free-radical unit and its copper(II) complex as potential hR2 RNR inhibitors Chemical Communications. ,vol. 49, pp. 10007- 10009 ,(2013) , 10.1039/C3CC45743E

Quinn P. Peterson, Danny C. Hsu, David R. Goode, Chris J. Novotny, Ryan K. Totten, Paul J. Hergenrother, Procaspase-3 Activation as an Anti-Cancer Strategy: Structure-Activity Relationship of Procaspase-Activating Compound 1 (PAC-1) and its Cellular Co-Localization with Caspase-3 Journal of Medicinal Chemistry. ,vol. 52, pp. 5721- 5731 ,(2009) , 10.1021/JM900722Z

Diana C. West, Yan Qin, Quinn P. Peterson, Diana L. Thomas, Rahul Palchaudhuri, Karen C. Morrison, Pamela W. Lucas, Amy E. Palmer, Timothy M. Fan, Paul J. Hergenrother, Differential effects of procaspase-3 activating compounds in the induction of cancer cell death. Molecular Pharmaceutics. ,vol. 9, pp. 1425- 1434 ,(2012) , 10.1021/MP200673N

Mingze Qin, Xin Zhai, Hongbo Xie, Junjie Ma, Kuan Lu, Yu Wang, Lihui Wang, Yucheng Gu, Ping Gong, Design and synthesis of novel 2-(4-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)pyridines as potential antitumor agents European Journal of Medicinal Chemistry. ,vol. 81, pp. 47- 58 ,(2014) , 10.1016/J.EJMECH.2014.04.059

Wei Zhou, Xiaofeng Liu, Zhengchao Tu, Lianwen Zhang, Xin Ku, Fang Bai, Zhenjiang Zhao, Yufang Xu, Ke Ding, Honglin Li, Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant Journal of Medicinal Chemistry. ,vol. 56, pp. 7821- 7837 ,(2013) , 10.1021/JM401045N

Pasi A. Jänne, Joachim von Pawel, Roger B. Cohen, Lucio Crino, Charles A. Butts, Steven S. Olson, Irene A. Eiseman, Alberto A. Chiappori, Beow Y. Yeap, Peter F. Lenehan, Kathy Dasse, Meredith Sheeran, Philip D. Bonomi, Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non-Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 25, pp. 3936- 3944 ,(2007) , 10.1200/JCO.2007.11.1336

Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238

Wenjun Zhou, Dalia Ercan, Pasi A. Jänne, Nathanael S. Gray, Discovery of selective irreversible inhibitors for EGFR-T790M Bioorganic & Medicinal Chemistry Letters. ,vol. 21, pp. 638- 643 ,(2011) , 10.1016/J.BMCL.2010.12.036

Juswinder Singh, Russell C Petter, Arthur F Kluge, Targeted covalent drugs of the kinase family Current Opinion in Chemical Biology. ,vol. 14, pp. 475- 480 ,(2010) , 10.1016/J.CBPA.2010.06.168